Development of a high-performance liquid chromatographic method for bioequivalence study of flavoxate tablets

Ming Thau Sheu, Geng Cheng Yeh, Wen Ting Ke, Hsiu O. Ho

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

An improved HPLC method was developed for the concentration determination of the metabolite of flavoxate, 3-methyl-flavone-8-carboxylic acid (MFCA), in plasma in an attempt to compare two flavoxate tablet formulations. This HPLC method was validated by examining the precision and the accuracy for inter-day and intra-day runs in a linear concentration range of 0.1-24 μg/ml. The coefficients of variation (C.V.) of inter-day and intra-day assays were 0.24-7.18% and 0.06-5.70%, respectively. The standard errors of mean (S.E.M.) were -0.004-8.68% and -2.52-4.86% for inter-day and intra-day assays, respectively. Bioequivalence of the two formulations was determined on 12 normal healthy male volunteers in a single-dose, two-period, two-sequence, two-treatment crossover study. MFCA plasma concentrations were analyzed with this validated HPLC method. The normal pivotal parameters, AUC0-last, AUC0-inf and Cmax, were calculated and compared using the SAS General Linear Model computer program. The two one-sided t distribution test was also performed, as well as the 90% confidence-interval method, for the mean difference of the three pivotal parameters. The results suggest that these two flavoxate tablet formulations are non-bioequivalent when orally administered in a 400-mg dose of two tablets. This result was consistent with the in vitro dissolution of these two formulations.

Original languageEnglish
Pages (from-to)79-86
Number of pages8
JournalJournal of Chromatography B: Biomedical Sciences and Applications
Volume751
Issue number1
DOIs
Publication statusPublished - Feb 10 2001

Fingerprint

Flavoxate
flavone
Tablets
Carboxylic Acids
Assays
Liquids
Plasmas
Metabolites
Computer program listings
Dissolution

Keywords

  • Bioequivalence study
  • Flavoxate

ASJC Scopus subject areas

  • Chemistry(all)

Cite this

@article{60527670e81749ea9372ae874242513b,
title = "Development of a high-performance liquid chromatographic method for bioequivalence study of flavoxate tablets",
abstract = "An improved HPLC method was developed for the concentration determination of the metabolite of flavoxate, 3-methyl-flavone-8-carboxylic acid (MFCA), in plasma in an attempt to compare two flavoxate tablet formulations. This HPLC method was validated by examining the precision and the accuracy for inter-day and intra-day runs in a linear concentration range of 0.1-24 μg/ml. The coefficients of variation (C.V.) of inter-day and intra-day assays were 0.24-7.18{\%} and 0.06-5.70{\%}, respectively. The standard errors of mean (S.E.M.) were -0.004-8.68{\%} and -2.52-4.86{\%} for inter-day and intra-day assays, respectively. Bioequivalence of the two formulations was determined on 12 normal healthy male volunteers in a single-dose, two-period, two-sequence, two-treatment crossover study. MFCA plasma concentrations were analyzed with this validated HPLC method. The normal pivotal parameters, AUC0-last, AUC0-inf and Cmax, were calculated and compared using the SAS General Linear Model computer program. The two one-sided t distribution test was also performed, as well as the 90{\%} confidence-interval method, for the mean difference of the three pivotal parameters. The results suggest that these two flavoxate tablet formulations are non-bioequivalent when orally administered in a 400-mg dose of two tablets. This result was consistent with the in vitro dissolution of these two formulations.",
keywords = "Bioequivalence study, Flavoxate",
author = "Sheu, {Ming Thau} and Yeh, {Geng Cheng} and Ke, {Wen Ting} and Ho, {Hsiu O.}",
year = "2001",
month = "2",
day = "10",
doi = "10.1016/S0378-4347(00)00451-5",
language = "English",
volume = "751",
pages = "79--86",
journal = "Journal of Chromatography B: Biomedical Sciences and Applications",
issn = "0378-4347",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - Development of a high-performance liquid chromatographic method for bioequivalence study of flavoxate tablets

AU - Sheu, Ming Thau

AU - Yeh, Geng Cheng

AU - Ke, Wen Ting

AU - Ho, Hsiu O.

PY - 2001/2/10

Y1 - 2001/2/10

N2 - An improved HPLC method was developed for the concentration determination of the metabolite of flavoxate, 3-methyl-flavone-8-carboxylic acid (MFCA), in plasma in an attempt to compare two flavoxate tablet formulations. This HPLC method was validated by examining the precision and the accuracy for inter-day and intra-day runs in a linear concentration range of 0.1-24 μg/ml. The coefficients of variation (C.V.) of inter-day and intra-day assays were 0.24-7.18% and 0.06-5.70%, respectively. The standard errors of mean (S.E.M.) were -0.004-8.68% and -2.52-4.86% for inter-day and intra-day assays, respectively. Bioequivalence of the two formulations was determined on 12 normal healthy male volunteers in a single-dose, two-period, two-sequence, two-treatment crossover study. MFCA plasma concentrations were analyzed with this validated HPLC method. The normal pivotal parameters, AUC0-last, AUC0-inf and Cmax, were calculated and compared using the SAS General Linear Model computer program. The two one-sided t distribution test was also performed, as well as the 90% confidence-interval method, for the mean difference of the three pivotal parameters. The results suggest that these two flavoxate tablet formulations are non-bioequivalent when orally administered in a 400-mg dose of two tablets. This result was consistent with the in vitro dissolution of these two formulations.

AB - An improved HPLC method was developed for the concentration determination of the metabolite of flavoxate, 3-methyl-flavone-8-carboxylic acid (MFCA), in plasma in an attempt to compare two flavoxate tablet formulations. This HPLC method was validated by examining the precision and the accuracy for inter-day and intra-day runs in a linear concentration range of 0.1-24 μg/ml. The coefficients of variation (C.V.) of inter-day and intra-day assays were 0.24-7.18% and 0.06-5.70%, respectively. The standard errors of mean (S.E.M.) were -0.004-8.68% and -2.52-4.86% for inter-day and intra-day assays, respectively. Bioequivalence of the two formulations was determined on 12 normal healthy male volunteers in a single-dose, two-period, two-sequence, two-treatment crossover study. MFCA plasma concentrations were analyzed with this validated HPLC method. The normal pivotal parameters, AUC0-last, AUC0-inf and Cmax, were calculated and compared using the SAS General Linear Model computer program. The two one-sided t distribution test was also performed, as well as the 90% confidence-interval method, for the mean difference of the three pivotal parameters. The results suggest that these two flavoxate tablet formulations are non-bioequivalent when orally administered in a 400-mg dose of two tablets. This result was consistent with the in vitro dissolution of these two formulations.

KW - Bioequivalence study

KW - Flavoxate

UR - http://www.scopus.com/inward/record.url?scp=0035835420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035835420&partnerID=8YFLogxK

U2 - 10.1016/S0378-4347(00)00451-5

DO - 10.1016/S0378-4347(00)00451-5

M3 - Article

C2 - 11232858

AN - SCOPUS:0035835420

VL - 751

SP - 79

EP - 86

JO - Journal of Chromatography B: Biomedical Sciences and Applications

JF - Journal of Chromatography B: Biomedical Sciences and Applications

SN - 0378-4347

IS - 1

ER -